AI-powered diagnostic assistant for acute ischemic stroke detection, delivering 93% of accuracy within just 15–30 seconds. It is based on native CT scans without perfusion – the standard scans that are fast and widely available in any stroke unit.
Stroke is the 2nd leading cause of death in Europe, affecting over 1.1 million people annually. ~80% of strokes are ischemic, caused by blood clots blocking blood flow to the brain 1,2
Reference
In ischemic stroke, every minute without treatment costs ~2 million neurons. Rapid and accurate diagnosis is critical, but hard to achieve under the current conditions 1,2,3
Reference
Radiologists are overloaded, working under time pressure and fatigue. Stroke-related CT interpretation remains error-prone, with diagnostic accuracy ranging from 45% to 88% 1,2
Reference
Hospitals lack a solution that can reliably, instantly, and accurately assist stroke diagnosis. While research confirms AI’s potential native AI ischemic stroke detection remains a niche with very few viable solutions 1,2
Reference
SINAPSE is AI-driven diagnostic assistant for stroke detection, delivering 93% of accuracy within just 15–30 seconds, making it one of the most effective AI tools of its kind globally.
Unique medical data access enables the exclusive development of this and other medical AI tools.
Years of R&D completed and over €500,000 in initial funding already put into the product.
EU initiatives are promoting the development and adoption of such solutions, making this a strong moment to enter the market and establish an early competitive position.
Most AI tools focus on contrast enhanced CT scans, which are more complex and costly, and are typically used when the initial diagnosis is already known. SINAPSE analyses the initial native CT scans without perfusion – the standard, non-contrast images available immediately and without extra equipment. This allows earlier stroke detection at a lower cost and with greater accessibility in emergency settings.
ACCURACY
Currently SINAPSE has become one of the most effective AI tools of its kind globally, with an accuracy of 93%.
SPEED
While doctors and other AI tools can take up to 20 minutes to deliver results, SINAPSE presents result in just 15 to 30 seconds.
INTEGRATION
Unlike competitors who require separate, standalone solutions, SINAPSE integrates directly into existing hospital systems – no new platforms or logins. Intuitive by design.
FOCUS
Real-time AI assistance focusing on the earliest and most critical step in stroke diagnosis. It enables emergency and radiology teams to quickly assess and prioritize critical cases.
Validated over 5 years in partnership with Pauls Stradins Clinical University Hospital and leading stroke experts in Latvia. System was trained on thousands of anonymized CT scans, curated and annotated by experienced radiologists.
Key results from clinical validation:
±0.62 ASPECTS score difference (vs. ±1.5 for average diagnosis)
93% diagnostic accuracy in stroke detection
15–30 seconds processing time per scan
Fully validated in hospital environment, compatible with existing systems
Continuous refinement through clinician feedback and new patient cases
More than a theoretical model — our clinically validated system is already supporting faster diagnostics and more accurate treatment decisions in real-world stroke care.
AGNIS JAKUBOVICS
Co-Founder
Board Member
ELVIJS GULBIS
Business Dev and Sales
Product Developer
LINA BRINGE
Chief Delivery Officer
AI Researcher
med. Dr. ANDRIS VEISS
Co-Founder
Radiologist
med. PhD Prof. KARLIS KUPCS
Co-Founder
Medical Lead Radiologist
SERGEJS IVANOVS
Sr. AI Research and Dev
AI Developer
SINAPSE is an AI-powered diagnostic assistant for acute ischemic stroke detection that supports radiologists by identifying abnormalities in CT scans in real-time
Unlike most stroke detection AIs, SINAPSE analyses native (non-contrast) CT scans, requiring no extra equipment and facing very little competition
It processes the data within 15-30 seconds and has reached an accuracy of 93%, making it one of the most effective AI tools of its kind globally
Already in use by two leading medical institutions in Latvia, where it has received positive reviews regarding its quality and usefulness in existing hospital workflows. These partnerships support clinical validation and help refine upcoming features and expanded spectrum of diagnoses.
ELVIJS GULBIS
Business Dev and Sales
Product Developer
TEL: +371 277 309 67
MAIL: Elvijs.Gulbis@sinapsedx.com
SIA “AKA Sinapse’’
Registration No.: 40203500743
VAT No.: LV40203500743
Legal Address: Īvandes St. 5, Riga, LV-1004, Latvia
Bank: AS SWEDBANK
SWIFT: HABALV22
IBAN: LV29 HABA 0551 0549 8549 7
